Joel M Mor1, Ludwig M Heindl1. 1. Department of Ophthalmology, University of Cologne, Cologne, Germany.
Abstract
AIM: In this review, we outline similarities between conjunctival and skin melanoma as well as the effectiveness of combined BRAF/MEK inhibition in melanoma, and discuss the applicability of these agents in conjunctival melanoma. METHODS: The study provides a PubMed literature review. RESULTS: Conjunctival melanoma and skin melanoma are genetically and phenotypically related. Both tumors typically harbor BRAF mutations in more than 50% of cases. New targeted therapies in metastatic skin melanoma include selective inhibition of BRAF and MEK. Combined BRAF/MEK inhibition has revolutionized the treatment of metastatic skin melanoma, significantly improving patients' prognoses. While these new substances have been investigated extensively in the treatment of skin melanoma, comparable studies in conjunctival melanoma do not exist owing to the rarity of the malignancy. CONCLUSIONS: The application of combined BRAF/MEK inhibition in metastatic or unresectable conjunctival melanoma shows great potential for improving patients' prognoses. Future studies are needed to investigate the assumed benefit.
AIM: In this review, we outline similarities between conjunctival and skin melanoma as well as the effectiveness of combined BRAF/MEK inhibition in melanoma, and discuss the applicability of these agents in conjunctival melanoma. METHODS: The study provides a PubMed literature review. RESULTS:Conjunctival melanoma and skin melanoma are genetically and phenotypically related. Both tumors typically harbor BRAF mutations in more than 50% of cases. New targeted therapies in metastatic skin melanoma include selective inhibition of BRAF and MEK. Combined BRAF/MEK inhibition has revolutionized the treatment of metastatic skin melanoma, significantly improving patients' prognoses. While these new substances have been investigated extensively in the treatment of skin melanoma, comparable studies in conjunctival melanoma do not exist owing to the rarity of the malignancy. CONCLUSIONS: The application of combined BRAF/MEK inhibition in metastatic or unresectable conjunctival melanoma shows great potential for improving patients' prognoses. Future studies are needed to investigate the assumed benefit.
Authors: Cynthia Cohen; Angel Zavala-Pompa; Judy H Sequeira; Mamoru Shoji; Deborah G Sexton; George Cotsonis; Francesca Cerimele; Baskaran Govindarajan; Nada Macaron; Jack L Arbiser Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Satori Iwamoto; Robert C Burrows; Hans E Grossniklaus; James Orcutt; Robert E Kalina; Michael Boehm; Mark A Bothwell; Rodney Schmidt Journal: Arch Ophthalmol Date: 2002-12
Authors: I Bedrosian; M B Faries; D Guerry; R Elenitsas; L Schuchter; R Mick; F R Spitz; L P Bucky; A Alavi; D E Elder; D L Fraker; B J Czerniecki Journal: Ann Surg Oncol Date: 2000-05 Impact factor: 5.344
Authors: Satori Iwamoto; Robert C Burrows; Robert E Kalina; David George; Michael Boehm; Mark A Bothwell; Rodney Schmidt Journal: Arch Ophthalmol Date: 2002-04
Authors: Pamela M Pollock; Ursula L Harper; Katherine S Hansen; Laura M Yudt; Mitchell Stark; Christiane M Robbins; Tracy Y Moses; Galen Hostetter; Urs Wagner; John Kakareka; Ghadi Salem; Tom Pohida; Peter Heenan; Paul Duray; Olli Kallioniemi; Nicholas K Hayward; Jeffrey M Trent; Paul S Meltzer Journal: Nat Genet Date: 2002-11-25 Impact factor: 38.330
Authors: Jan-Peter Glossmann; Nicole Skoetz; Barbara Starbatty; Martina Bischoff; Serge Leyvraz; Henrike Westekemper; Ludwig M Heindl Journal: Ophthalmologe Date: 2018-06 Impact factor: 1.059
Authors: Natasha M van Poppelen; Jolique A van Ipenburg; Quincy van den Bosch; Jolanda Vaarwater; Tom Brands; Bert Eussen; Frank Magielsen; Hendrikus J Dubbink; Dion Paridaens; Erwin Brosens; Nicole Naus; Annelies de Klein; Emine Kiliç; Robert M Verdijk Journal: Int J Mol Sci Date: 2021-05-28 Impact factor: 5.923